

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) An isolated protein comprising SEQ ID NOS: 9, 13, 17, 21 or 25.

2-10 (Canceled)

11. (Original) An isolated protein comprising SEQ ID NOS: 7, 11, 15, 19 or 23.

12-18 (Canceled)

19. (Previously presented) The protein of claim 1 wherein the protein is O-linked with β -(1-3)-Gal-GalNac.

20. (Original) A composition comprising a therapeutically effective amount of a protein of claim 19 in a pharmaceutically acceptable carrier.

21. (Original) The composition of claim 20 additionally comprising hyaluronan or hylan.

22-35 (Canceled)

36. (New) The protein of claim 1, wherein the protein is O-linked with keratin sulfate.

37. (New) The protein of claim 1, wherein the protein is O-linked with chondroitin sulfate.

38. (New) The composition of claim 20, wherein the composition is formulated for injection.

39. (New) The composition of claim 20, wherein the composition is encapsulated.

40. (New) The composition of claim 20, wherein the composition further comprises a matrix.

41. (New) The composition of claim 20, wherein the composition further comprises a local anesthetic.

42. (New) The composition of claim 20, wherein the composition further comprises a cytokine.

43. (New) The composition of claim 20, wherein the composition further comprises a lymphokine.

44. (New) The composition of claim 20, wherein the composition further comprises a thromolytic factor.

45. (New) The composition of claim 20, wherein the composition further comprises an antithrombolytic factor.

46. (New) The composition of claim 20, wherein the composition further comprises an anti-inflammatory agent.

47. (New) The protein of claim 11, wherein the protein is O-linked with β -(1-3)-Gal-GalNac.

48. (New) A composition comprising a therapeutically effective amount of a protein of claim 47 in a pharmaceutically acceptable carrier.

49. (New) The composition of claim 48, additionally comprising hyaluronan or hylan.

50. (New) The composition of claim 48, wherein the composition is formulated for injection.

51. (New) The composition of claim 48, wherein the composition is encapsulated.

52. (New) The composition of claim 48, wherein the composition further comprises a matrix.

53. (New) The composition of claim 48, wherein the composition further comprises a local anesthetic.

54. (New) The composition of claim 48, wherein the composition further comprises a cytokine.

55. (New) The composition of claim 48, wherein the composition further comprises a lymphokine.

56. (New) The composition of claim 48, wherein the composition further comprises a thromolytic factor.

57. (New) The composition of claim 48, wherein the composition further comprises an antithrombolytic factor.

58. (New) The composition of claim 48, wherein the composition further comprises an anti-inflammatory agent.